FOR IMMEDIATE RELEASE
Date: June 2026
Contact: media@ikongroupinvestments.com
IKON Group Expands Healthcare Portfolio with Kynetide Peptides Acquisition
HOUSTON, TX — IKON Group Investments, a global holding company headquartered in Houston, Texas, today announced the strategic acquisition of Kynetide Peptides, a leading developer of advanced peptide therapy solutions for performance optimization and longevity.
“Kynetide Peptides represents everything we look for in a portfolio company — innovative products backed by real science, a passionate management team, and a large and growing market opportunity,” said Rhett Kenagy, Founder and CEO of IKON Group Investments. “Peptide therapy is at an inflection point, and Kynetide is perfectly positioned to become the category leader.”
The acquisition adds to IKON Group’s growing healthcare and life sciences portfolio, which includes Renew Republic Health and Renew Lab Group. Combined, these companies create a fully integrated healthcare value chain spanning R&D, manufacturing, and direct-to-consumer distribution.
###
About IKON Group Investments: IKON Group Investments is a Houston, Texas-based global holding company managing a diversified over $1 billion portfolio across healthcare, aerospace, biotechnology, real estate, energy, technology, and consumer sectors. For more information, visit ikongroupinvestments.com.